Amicus Therapeutics, Inc. (NASDAQ:FOLD) Insider Samantha Prout Sells 3,366 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Samantha Prout sold 3,366 shares of the company’s stock in a transaction on Friday, June 19th. The stock was sold at an average price of $15.00, for a total value of $50,490.00. Following the transaction, the insider now directly owns 20,501 shares in the company, valued at approximately $307,515. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

FOLD traded up $0.16 on Tuesday, reaching $15.56. The company’s stock had a trading volume of 3,089,019 shares, compared to its average volume of 3,406,775. Amicus Therapeutics, Inc. has a 1 year low of $6.25 and a 1 year high of $15.89. The business’s 50 day moving average is $12.31 and its 200 day moving average is $10.51. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.45 and a quick ratio of 4.31. The stock has a market cap of $4.02 billion, a price-to-earnings ratio of -11.99 and a beta of 1.29.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.07). The business had revenue of $60.53 million for the quarter, compared to analysts’ expectations of $57.21 million. Amicus Therapeutics had a negative net margin of 155.73% and a negative return on equity of 63.24%. As a group, research analysts forecast that Amicus Therapeutics, Inc. will post -1.06 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC grew its holdings in Amicus Therapeutics by 2.1% during the 4th quarter. Perceptive Advisors LLC now owns 25,132,364 shares of the biopharmaceutical company’s stock worth $244,789,000 after acquiring an additional 522,664 shares in the last quarter. BlackRock Inc. lifted its position in shares of Amicus Therapeutics by 1.8% during the first quarter. BlackRock Inc. now owns 21,239,016 shares of the biopharmaceutical company’s stock worth $196,248,000 after purchasing an additional 382,909 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Amicus Therapeutics by 8.1% during the first quarter. Janus Henderson Group PLC now owns 11,625,924 shares of the biopharmaceutical company’s stock worth $107,423,000 after purchasing an additional 867,308 shares during the last quarter. State Street Corp grew its stake in Amicus Therapeutics by 1.2% in the first quarter. State Street Corp now owns 11,129,151 shares of the biopharmaceutical company’s stock worth $102,833,000 after purchasing an additional 132,427 shares in the last quarter. Finally, Palo Alto Investors LP increased its holdings in Amicus Therapeutics by 3.5% in the fourth quarter. Palo Alto Investors LP now owns 7,413,920 shares of the biopharmaceutical company’s stock valued at $72,212,000 after buying an additional 251,000 shares during the last quarter.

Several research analysts have weighed in on FOLD shares. JPMorgan Chase & Co. restated a “buy” rating on shares of Amicus Therapeutics in a research report on Monday, June 8th. BidaskClub downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. BTIG Research began coverage on shares of Amicus Therapeutics in a report on Tuesday, June 16th. They set a “buy” rating and a $19.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a research report on Tuesday, June 16th. Finally, SVB Leerink reiterated a “market perform” rating and set a $19.00 target price on shares of Amicus Therapeutics in a report on Tuesday, May 19th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $19.08.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

See Also: What is the return on assets formula?

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.